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INTRODUCTION
The proportion and absolute number of older adults undergoing allogeneic hematopoietic cell transplantation (HCT) is rapidly rising such that almost 40% of transplant recipients are now 50 years and older.(1) A growing number of reports now demonstrate the utility of HCT in older adults with long-term outcomes that compare favorably to non-transplant series and transplant survival rates that approach those seen in younger adults.(2-4) Most authors have thus concluded that older age should no longer remain a barrier to transplant. However, despite these promising advances, only a small fraction of older adults with high-risk hematologic malignancies actually undergo HCT presumably, in part, due to ongoing concerns regarding tolerability and transplant success in this population. (5, 6) A major barrier to patient selection for aggressive therapy remains the lack of health status information reported in treatment studies of older patients with hematologic malignancies. (7) Better characterization of health-related prognostic factors may aid in pretransplant risk stratification, thereby facilitating early referral of appropriate candidates. Aside from age, traditional tools used for HCT prognostication have included disease status, donor type, graft source, and physician-rated Karnofsky performance status (KPS).(8) A major advancement in transplant prognostication was achieved when Sorror and colleagues developed the hematopoietic cell transplantation-specific comorbidity index (HCT-CI), a comorbidity scoring system that predicts for transplant-related toxicity and overall survival (OS).(9-11) The HCT-CI is now incorporated routinely into pre-transplant assessment. However, as a single domain, comorbidity cannot sufficiently describe all areas of health relevant to older adults. For example, simple functional impairments (e.g., difficulty walking) may have an equivalent or greater impact on long-term survival. (12) A more comprehensive assessment of health across domains relevant to older adults may be obtained through a geriatric assessment (GA). Originally developed by geriatricians as a multidisciplinary evaluation of older patients, geriatric assessment is increasingly fundamental to the field of solid tumor oncology, where GA variables independently predict for chemotherapy toxicity and mortality and may facilitate guided interventions in older cancer patients. (13) (14) (15) Despite recommendations regarding the use of GA from the International Society of Geriatric Oncology(16) and practice guidelines outlined by the National Comprehensive Cancer Network, this powerful tool has not been described for transplant patients. This likely stems from the fact that HCT recipients have historically been younger than the typical geriatric population, but may also be due to the widely held belief that only fit older adults undergo transplant. We recently reported a high prevalence of health-related vulnerabilities uncovered by prospective GA among older HCT recipients. (17) We now report on the prognostic significance of pre-transplant GA in a large series of older HCT recipients.
METHODS

Patient Population and Treatment Regimen
Patients ≥ 50 years and scheduled to undergo allogeneic HCT at The University of Chicago were eligible for inclusion, as previously described.(17) We selected a threshold age of 50 years, as the optimal age for GA in this population has not been studied and this was the age where reduction in transplant regimen intensity may be justified.(18) A trained research assistant or nurse administered the GA within one month prior to initiation of transplant conditioning.
Occasionally, GA occurred 1-2 days after conditioning began. The treating physician determined suitability to undergo HCT and appropriate HCT treatment plan independent of GA results. After completing a prospective institutional review board approved protocol,(17) GA continued on a clinical basis. All patients provided written informed consent.
Geriatric Assessment Variables
The GA consisted of six distinct domains of health: functional status, frailty, comorbidity, mental health, nutritional status, and degree of inflammation. 
Outcomes
The median follow-up duration for surviving patients was 36 months (range, 3-121).
During this time, 113 patients died, 67 without relapse (NRM), and 46 after disease relapse.
The median OS was 15.6 months and the probabilities of OS, NRM, and relapse at 2 years were 45% (95% CI 38-52), 33% (95% CI 26-39), and 35% (95% CI 28-42), respectively.
Univariate Analysis of 2-Year NRM, Relapse, and OS
Unadjusted effects of routine clinical parameters and GA measures on transplant outcomes are reported in Table 3 . The following variables were significantly associated with 8 inferior OS: age ≥ 60 years (P = .0007), ablative conditioning regimen (P = .048), CMV+ donor and/or recipient (P= .03), higher HCT-CI (P = .03) IADL limitations (P < .0001), slow walk speed (P =.01), lower mental health (P = .01), low albumin (P = .008), and high CRP (P =.0003).
Age ≥ 60 years (P = .0005), IADL limitations (P = .0003), higher HCT-CI (P = .03), and high CRP (P = .029) significantly increased risk of NRM, whereas only high disease risk (P = .02) and slow walk speed (P = .03) were associated with disease relapse.
Adjusted Model
After adjusting for routine clinical parameters of age, HCT-CI, disease risk, and regimen intensity, IADL limitations (P < .0001), slow walk speed (P = .01), low SF36-MCS (P = .01), and high CRP (P <.001) remained significantly associated with worse OS (Table 4) .
Simplified risk score
We devised a simple stratification tool for survival by adding the most prognostic GA measure, IADL, to the HCT-CI ( Figure 1A ). This was motivated by prior work demonstrating an additive effect of functional status and comorbidity for transplant prognostication.(9, 33) High HCT-CI and any IADL limitation were given 1 point and thus patients could have 0, 1 or 2 points total. Relative to no points, one point conferred significantly inferior 2-year survival (44% vs 62%; HR 1.74, 95% CI 1.1-2.86; P = .026), and 2 points resulted in only a 13% 2-year survival rate (HR 3.66, 95% CI 2.1-6.4; P < .001). The IADL/HCT-CI risk score was independent of disease risk, as high disease risk was found in 43.6%, 53.2%, and 43.3% of patients scores of 0, 1, and 2, respectively (P = .47).
Age and GA
We further stratified the adjusted survival analyses by the two age cohorts of 50-59 years versus ≥ 60 years (Table 4) . HRs for all GA measures were quantitatively higher in the older age cohort, suggesting a greater predictive effect of GA in older transplant recipients. The prognostic effect of the IADL/HCT-CI risk score was similarly amplified in the older cohort ( Figures 1B, 1C ). For example, 2-year OS for those ≥ 60 years with an IADL/HCT-CI score of 1 was 29% (relative to 53% for 50-59 year olds for a score of 1), and 2 OS for patients ≥ 60 years with a score of 2 was 0%.
DISCUSSION
In this study, the first to report on the use of prospective geriatric assessment specifically in a large group of older allogeneic HCT recipients, we demonstrate that Geriatric Assessment prior to HCT offers substantial prognostic value. After controlling for several established predictors of transplant outcome, health impairments across geriatric domains of functional status, comorbidity, mental health, and systemic inflammation all retained a significant association with decreased survival following transplantation. Our findings extend the utility of GA previously established in solid tumor oncology (13, 15, 16 ) and build upon a nascent literature in the hematologic malignancies.(7, 34)
As growing numbers of older adults are considered for HCT, an intensive and expensive therapeutic modality, more accurate assessment of "biological age" rather than simply chronological age has gained importance. Implementation of GA tools into the routine pretransplant work-up for older adults may move us a step closer to achieving this distinction. These novel results raise intriguing questions about how to best apply GA in transplant patients. First, we recommend larger confirmatory studies focusing on the GA tools most prognostic in our study such as IADL, walk speed, and self-report mental health targeting adult HCT recipients 60 years and older. Our inclusion of an inflammatory biomarker associated with aging and functional decline(37) (i.e., CRP) in a GA is not standard. The mechanisms behind inflammation in patients prior to transplant may relate to infection, disease, hepatic dysfunction and/or dysregulated inflammation. Given the prognostic relevance, CRP warrants study not only as a simple readily available prognostic marker, but also as a target for anti-inflammatory therapeutic strategies. Widespread adoption of GA will require paring the GA down to the essential components to create GA derived scoring systems that mirror larger geriatric oncology studies.(14, 38) A validated tool should help guide physicians on appropriate transplant referrals for older adults, improve patient counseling, and provide a means to more accurately describe the health status of older adults in future transplant studies. Pending larger confirmatory studies, the IADL/HCT-CI risk score could be tested as this only requires the IADL questionnaire as the HCT-CI is routine prior to transplant.
The value of detailed health assessment by GA lies not only in predicting survival, but additionally and perhaps more importantly, in creating a transplant supportive care package targeted to GA defined limitations. For example, unlike comorbidity, which may be difficult to modify in the peri-transplant period, impairments in both functional status and mental health may be amenable to aggressive physical therapy or strengthening psychological support, respectively.
Moreover, a GA often reveals patient assets that can be leveraged to mitigate limitations. For example, strong social support can be actively engaged to facilitate functional recovery in those with functional impairment or ensure medication adherence in patients requiring medication management assistance.
There are several limitations to this study. Our decision to include patients beginning at 50 years led to a relatively younger cohort than the typical GA study. Our findings indicate that the prognostic impact of GA impairments is pronounced in HCT recipients ≥ 60 years relative to those 50-59 years of age. In contrast to recent reports on HCT outcomes in older age,(2-4) we found older age to be adversely prognostic. This may relate to our study population, which included varying diseases, disease risk, and conditioning regimen intensities. Even as the largest study of GA in transplant recipients, the large number of variables prevents modeling all clinical and GA variables together or generating a validation set in this study cohort. This will require a large cooperative group study. We could also not determine whether pre-transplant limitations were derived from prior treatments (e.g., induction chemotherapy) and/or were present at diagnosis as we lacked GA data at diagnosis or serially. For example, the surprising association of slow walk speed to disease relapse, rather than NRM, would be clarified by confirmation in a uniform population (e.g., AML in remission) and/or walk speed measured at diagnosis. Finally, our GA did not include all domains that may be of importance such as cognition and caregiver support. Our institution has now implemented a GA validated by Hurria and colleagues, (39) which includes these potentially relevant domains.
In conclusion, this study demonstrates the potential prognostic value of geriatric assessment applied to older HCT recipients. If validated, a comprehensive health status assessment including at least some GA measures may aid in transplant prognostication and patient selection, and will ultimately provide the basis for future interventions targeted at reducing transplant morbidity and mortality while maintaining the global health of older HCT recipients. 
